News about "Lupin"

Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialise YUVEZZI in Europe

Lupin and Tenpoint Therapeutics partner to commercialise YUVEZZI in the European Union (EU), The UK, Switzerland, Norway, and Iceland and expand access to the once-daily dual-agent eye drop for presbyopia.

Lupin | 20/08/2026 | By News Bureau

Lupin Announces Approval from US FDA for Pitolisant Tablets

Lupin receives US Food and Drug Administration (FDA) approval for Pitolisant Tablets, 4.45 mg and 17.8 mg, a generic version of Wakix, for indications covered by the approved labeling.

Lupin | 17/08/2026 | By News Bureau

Lupin's US Business May Moderate After Strong Q1, Says Equirus Securities

Equirus Securities expects Lupin’s US business to moderate amid rising competition, while new launches and expanding chronic and international portfolios could support overall growth.

Lupin | 14/08/2026 | By News Bureau

US FDA Approves Lupin's Generic Diazepam Injection in Prefilled Syringe Format

Lupin has secured US FDA approval for its generic diazepam injection USP in a single-dose prefilled syringe format. The bioequivalent version of Roche's Valium injection expands the company's US injectable portfolio and addresses a market valued at nearly USD 78 million annually.

Lupin | 04/08/2026 | By News Bureau

Lupin Launches Generic Sugammadex Injection in the US Following FDA Approval

Lupin launches Sugammadex Injection in the United States after receiving US FDA approval for its Abbreviated New Drug Application. The bioequivalent version of Merck's Bridion Injection is indicated for reversing neuromuscular blockade in adult and paediatric patients aged two years and older undergoing surgery.

Lupin | 31/07/2026 | By News Bureau

Lupin Spins Out 2 Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy

Lupin has spun off two oncology programs into Kaveri Therapeutics, retaining a significant equity stake while providing seed funding and exclusive program rights.

Lupin | 22/07/2026 | By News Bureau

Lupin Secures EMA Approval for Expanded NaMuscla Pediatric Use

Lupin has received EMA approval to expand the pediatric indication of NaMuscla, including two new capsule strengths of 62 mg and 83 mg.

Lupin | 03/07/2026 | By News Bureau |  341

Lupin Launches Azilsartan Medoxomil Tablets in US

Lupin has launched Azilsartan Medoxomil Tablets in the US, a bioequivalent generic version of Edarbi, indicated for the treatment of hypertension in adults.

Lupin | 17/06/2026 | By News Bureau |  111

Lupin Partners with ERN to Launch Luforbec in Spain

Lupin has partnered with ERN to launch Luforbec (beclometasone/formoterol) pMDI in Spain, combining Lupin’s respiratory expertise and advanced inhaler manufacturing capabilities with ERN’s strong market presence to expand access to high-quality respiratory care for patients across the country.

Lupin | 08/06/2026 | By News Bureau |  108

Lupin Receives US FDA Approval for Sodium Sulfate, Magnesium Sulfate and Potassium Chloride Tablets

Lupin has received US FDA approval for its Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets, a bioequivalent to Reference Listed Drug (RLD) Sutab Tablets of Azurity Pharmaceuticals.

Lupin | 02/06/2026 | By News Bureau |  106